|
HANAFUSA Norio
Department School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine Position Professor |
|
| Article types | Original article |
| Language | English |
| Peer review | Non peer reviewed |
| Title | Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19: a case report |
| Journal | Formal name：Intestinal research Abbreviation：Intest Res ISSN code：15989100/15989100 |
| Domestic / Foregin | Foregin |
| Volume, Issue, Page | 20(1),pp.150-155 |
| Author and coauthor | KOROKU Miki, OMORI Teppei*, KAMBAYASHI Harutaka, MURASUGI Shun, KURIYAMA Tomoko, IKARASHI Yuichi, YONEZAWA Maria, ARIMURA Ken, KARASAWA Kazunori, HANAFUSA, Norio, KAWANA Masatoshi, TOKUSHIGE Katsutoshi |
| Publication date | 2022/01 |
| Summary | Coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is now a pandemic. Although several treatment guidelines have been proposed for patients who have both inflammatory bowel disease and COVID-19, immunosuppressive therapy is essentially not recommended, and the treatment options are limited. Even in the COVID-19 pandemic, adjuvant adsorptive granulocyte and monocyte apheresis may safely bring ulcerative colitis (UC) into remission by removing activated myeloid cells without the use of immunosuppressive therapy. Our patient was a 25-year-old Japanese male with UC and COVID-19. This is the first case report of the induction of UC remission with granulocyte and monocyte apheresis treatment for active UC associated with COVID-19. |
| DOI | 10.5217/ir.2020.00148 |
| PMID | 33902268 |